Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACM-001 Booster Vaccine Study in Healthy Adults
NCT05385991Phase 1Completed
- Sponsor
- ACM Biolabs
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Polymer-based Nanoparticles, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ACM-CpG in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by ACM Biolabs. Primary endpoint: Adverse Events. Started Jul 2022; status: completed.
02
Drugs
ACM-CpG
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05385991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385991.